PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches - PubMed (original) (raw)

Review

. 2009 May 1;8(9):1352-8.

doi: 10.4161/cc.8.9.8255. Epub 2009 May 23.

Affiliations

• PMID: 19305151
• PMCID: PMC3781181
• DOI: 10.4161/cc.8.9.8255

Review

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

Giovanni Ligresti et al. Cell Cycle. 2009.

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) are a group of lipid kinases that regulate signaling pathways involved in cell proliferation, adhesion, survival and motility. The PI3K pathway is considered to play an important role in tumorigenesis. Activating mutations of the p110alpha subunit of PI3K (PIK3CA) have been identified in a broad spectrum of tumors. Analyses of PIK3CA mutations reveals that they increase the PI3K signal, stimulate downstream Akt signaling, promote growth factor-independent growth and increase cell invasion and metastasis. In this review, we analyze the contribution of the PIK3CA mutations in cancer, and their possible implications for diagnosis and therapy.

PubMed Disclaimer

Figures

Figure 1. Description of PIK3CA and its functional domains with the most common somatic mutations.

Similar articles

• Human tumor mutants in the p110alpha subunit of PI3K.
  Liu Z, Roberts TM. Liu Z, et al. Cell Cycle. 2006 Apr;5(7):675-7. doi: 10.4161/cc.5.7.2605. Epub 2006 Apr 1. Cell Cycle. 2006. PMID: 16627990 Review.
• Oncogenic PI3K and its role in cancer.
  Samuels Y, Ericson K. Samuels Y, et al. Curr Opin Oncol. 2006 Jan;18(1):77-82. doi: 10.1097/01.cco.0000198021.99347.b9. Curr Opin Oncol. 2006. PMID: 16357568 Review.
• Oncogenic mutations of PIK3CA in human cancers.
  Samuels Y, Velculescu VE. Samuels Y, et al. Cell Cycle. 2004 Oct;3(10):1221-4. doi: 10.4161/cc.3.10.1164. Epub 2004 Oct 12. Cell Cycle. 2004. PMID: 15467468
• PTEN-deficient cancers depend on PIK3CB.
  Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C. Wee S, et al. Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62. doi: 10.1073/pnas.0802655105. Epub 2008 Aug 28. Proc Natl Acad Sci U S A. 2008. PMID: 18755892 Free PMC article.
• The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
  Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, Ohwada J, Ebiike H, Kuramoto S, Morita K, Yoshimura Y, Yamazaki T, Ishii N, Kondoh O, Aoki Y. Tanaka H, et al. Clin Cancer Res. 2011 May 15;17(10):3272-81. doi: 10.1158/1078-0432.CCR-10-2882. Epub 2011 May 10. Clin Cancer Res. 2011. PMID: 21558396

Cited by

• Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer.
  Park J, Cho SY, Chang ES, Sung M, Song JY, Jung K, Kim SS, Shin YK, Choi YL. Park J, et al. Cancer Res Treat. 2023 Jan;55(1):145-154. doi: 10.4143/crt.2022.001. Epub 2022 Apr 20. Cancer Res Treat. 2023. PMID: 35468270 Free PMC article.
• AKT1 and PIK3CA activating mutations in Moroccan bladder cancer patients´ biopsies and matched urine.
  El Ahanidi H, El Azzouzi M, Arrouchi H, Alaoui CH, Tetou M, Bensaid M, Oukabli M, Ameur A, Al Bouzidi A, El Mzibri M, Attaleb M. El Ahanidi H, et al. Pan Afr Med J. 2022 Jan 20;41:59. doi: 10.11604/pamj.2022.41.59.31383. eCollection 2022. Pan Afr Med J. 2022. PMID: 35317488 Free PMC article.
• Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth.
  Huang YS, Wu CC, Chang CC, Huang SF, Kuo HY, Shih HM. Huang YS, et al. Cell Mol Life Sci. 2022 Jun 19;79(7):367. doi: 10.1007/s00018-022-04399-8. Cell Mol Life Sci. 2022. PMID: 35718818 Free PMC article.
• The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
  Thompson KN, Whipple RA, Yoon JR, Lipsky M, Charpentier MS, Boggs AE, Chakrabarti KR, Bhandary L, Hessler LK, Martin SS, Vitolo MI. Thompson KN, et al. Oncotarget. 2015 Nov 3;6(34):35231-46. doi: 10.18632/oncotarget.6159. Oncotarget. 2015. PMID: 26497685 Free PMC article.
• Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
  Dirican E, Akkiprik M, Özer A. Dirican E, et al. Tumour Biol. 2016 Jun;37(6):7033-45. doi: 10.1007/s13277-016-4924-2. Epub 2016 Feb 26. Tumour Biol. 2016. PMID: 26921096 Review.

References

1. 1. Kumar A, Carrera AC. New functions for PI3K in the control of cell division. Cell Cycle. 2007;6:1696–8. doi: 10.4161/cc.6.14.4492. - DOI - PubMed
2. 1. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A. 2006;103:1475–9. doi: 10.1073/pnas.0510857103. - DOI - PMC - PubMed
3. 1. Corvera S, Czech MP. Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol. 1998;8:442–6. doi: 10.1016/S0962-8924(98)01366-X. - DOI - PubMed
4. 1. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell. 2002;111:293–303. doi: 10.1016/S0092-8674(02)01083-8. - DOI - PubMed
5. 1. Yoeli-Lerner M, Toker A. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle. 2006;5:603–5. doi: 10.4161/cc.5.6.2561. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central
  • Taylor & Francis

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal